Competitor Analysis: Her2 Receptor Antagonists

The present Competitive Intelligence Report about Her2 receptor antagonists provides a competitor evaluation in the field of Her2 (ErbB2) receptor targeting molecules for treatment of cancer as of September 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab) with 2008 sales US$ 4.8 bln and the development of resistance to trastuzumab treatment has spurred the discovery and development of efficacy enhanced versions of anti-Her2 antibodies or antibodies binding to an epitope different from that of trastuzumab. Other approaches include the development of therapeutic vaccines to specifically stimulate the immune system against Her2 positive cancer cells. Her2 receptor tyrosine kinase inhibitors with a broader target profile including other members of the Her receptor family or including other targets are also in development. More than 20 new molecular entities targeting Her2 are in clinical development up to phase III including vaccines, cells, proteins, antibodies and small molecules.

The report includes a compilation of current active projects in research and development of molecules targeting the Her2 (ErbB2) receptor. In addition, the report lists company-specific R&D pipelines of Her2 receptor targeting small molecules, antibodies, proteins, cells and vaccines. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.